Chinese API investigation unmasks scheme to conceal monopoly profits
Chinese antitrust regulators have dismantled a complex scheme in which Weifang Zhongyuan Pharma used exclusive-distribution arrangements and proxy invoicing to conceal monopoly profits from the sale of magnesium trisilicate, a gastrointestinal...To view the full article, register now.
Already a subscriber? Click here to view full article